Corrigendum to “Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphomaˮ [Biochem. Biophys. Res. Commun. 485 (1) 2017 144–151] (Biochemical and Biophysical Research Communications (2017) 485(1) (144–151), (S0006291X17303078), (10.1016/j.bbrc.2017.02.039))

The authors regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or HH must be corrected from “every 3 days” to “every 3–4 days” in the part of “Supplementary materials and methods”. The authors also regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or Su9T01 must be corrected from “two times per week for 2 weeks” to “on day 1, day 8, day 15, and day 21 post-cell injection” in the part of “Supplementary materials and methods”. These corrections do not change the conclusions of this manuscript. The authors would like to apologise for any inconvenience caused. The correct supplementary materials and methods. In vivo experimental therapy studies. Six-to eight-week-old female NOD/Shi-scid/IL-2Rγnull (NOG) or SCID mice (CLEA Japan) were given a single subcutaneous injection of 2 × 10⁶ MT-2 cells or HH cells suspended in 100 μL PBS-diluted matrigel (BD Biosciences). When the average tumor size reached an approximate volume of 100–150 mm³, the mice were intravenously injected with either PBS, mogamulizumab, or the JST-TFR09 antibody at doses of 10 mg/kg (MT-2) or 20 mg/kg (HH) body weight 4–5 times every 3–4 days. The length and width of each tumor were measured with a caliper twice per week and used to calculate the tumor volume (length × width²/2). For Kaplan-Meier survival analysis of mice, NOG mice were given a single intravenous injection of 1 × 10⁶ MT-2 or Su9T01 cells suspended in 100 μL PBS. At 3 days after inoculation of ATLL cells, the mice were intravenously injected with either PBS or JST-TFR09 on day 1, day 8, day 15, and day 21 post-cell injection. The survival rate of mice was observed for a period of 100 days. The authors would like to apologise for any inconvenience caused.